Failed tri­als for 16 IGF-1R in­hibitors and $1.6B lat­er: Time for bet­ter pre­clin­i­cal mod­els?

New re­search pub­lished Fri­day in JA­MA Net­work Open es­ti­mates that up­wards of $50 bil­lion to $60 bil­lion is spent an­nu­al­ly by bio­phar­ma com­pa­nies on failed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.